Literature DB >> 25100506

Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment.

Stephen Silberstein1, Sumit Patel.   

Abstract

INTRODUCTION: In this article, we will discuss pure menstrual migraine without aura (PMM) and menstrually related migraine without aura (MRM). Depending on the frequency and severity of their attacks, patients with PMM will likely need an acute treatment and/or short-term preventive plan. Of note, with the use of acute treatments and short-term preventive therapy there is risk of medication overuse if the patient does have pure menstrual migraine and is being treated for menstrually related migraine. AREAS COVERED: A PubMed, Cochrane Central, Medline, Ovid search provided articles relating to menstrual migraine pathophysiology and treatment. EXPERT OPINION: Long-term daily preventive treatment should be considered for patients with MRM and those with severe PMM. Miniprophylaxis can be used in PMM rather than daily preventive treatment. When considering the use of short-term miniprophylaxis, sumatriptan, zolmitriptan, naratriptan, and frovatriptan have shown efficacy; however, frovatriptan appears to be the triptan of choice based on overall efficacy. Oral contraceptives may be considered if patients do not respond to or cannot tolerate typical migraine preventive medications. In patients with migraine with aura, oral contraceptives should be used with caution as this may add to the risk of stroke in this population.

Entities:  

Keywords:  estrogen; menstrual; migraine; treatment

Mesh:

Substances:

Year:  2014        PMID: 25100506     DOI: 10.1517/14656566.2014.947959

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  7 in total

1.  Evaluation and management of migraine in midlife women.

Authors:  Jelena M Pavlović
Journal:  Menopause       Date:  2018-08       Impact factor: 2.953

Review 2.  Is there any association between migraine headache and polycystic ovary syndrome (PCOS)? A review article.

Authors:  Nahid Sarahian; Mahsa Noroozzadeh; Marzieh Saei Ghare Naz; Narges Eskandari-Roozbahani; Fatemeh Mahboobifard; Fahimeh Ramezani Tehrani
Journal:  Mol Biol Rep       Date:  2021-10-15       Impact factor: 2.316

3.  Analysis of Trigger Factors in Episodic Migraineurs Using a Smartphone Headache Diary Applications.

Authors:  Jeong-Wook Park; Min Kyung Chu; Jae-Moon Kim; Sang-Gue Park; Soo-Jin Cho
Journal:  PLoS One       Date:  2016-02-22       Impact factor: 3.240

4.  Prevalence and Clinical Factors of Migraine in Patients With Spontaneous Coronary Artery Dissection.

Authors:  Susan N Kok; Sharonne N Hayes; F Michael Cutrer; Claire E Raphael; Rajiv Gulati; Patricia J M Best; Marysia S Tweet
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

Review 5.  Acute and Preventive Management of Migraine during Menstruation and Menopause.

Authors:  Raffaele Ornello; Eleonora De Matteis; Chiara Di Felice; Valeria Caponnetto; Francesca Pistoia; Simona Sacco
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

6.  Brain structural and functional differences between pure menstrual migraine and menstrually-related migraine.

Authors:  Tao Xu; Yutong Zhang; Chen Wang; Huaqiang Liao; Siyuan Zhou; Dehua Li; Siying Huang; Yu Shi; Ziwen Wang; Jiao Chen; Fan-Rong Liang; Ling Zhao
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

Review 7.  Diagnosis and management of migraine in ten steps.

Authors:  Anna K Eigenbrodt; Håkan Ashina; Sabrina Khan; Hans-Christoph Diener; Dimos D Mitsikostas; Alexandra J Sinclair; Patricia Pozo-Rosich; Paolo Martelletti; Anne Ducros; Michel Lantéri-Minet; Mark Braschinsky; Margarita Sanchez Del Rio; Oved Daniel; Aynur Özge; Ayten Mammadbayli; Mihails Arons; Kirill Skorobogatykh; Vladimir Romanenko; Gisela M Terwindt; Koen Paemeleire; Simona Sacco; Uwe Reuter; Christian Lampl; Henrik W Schytz; Zaza Katsarava; Timothy J Steiner; Messoud Ashina
Journal:  Nat Rev Neurol       Date:  2021-06-18       Impact factor: 42.937

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.